Microscopic Polyangiitis (MPA) is inflammation of the small and sometimes medium sized blood vessels. In the past MPA was thought to be a type of PAN and patients would have been told they had PAN. It is now recognised that they are separate diseases.
In microscopic polyangiitis it is common for the smallest blood vessels (capillaries) of the lungs and kidneys to be damaged leading to reduced kidney function or kidney failure and breathlessness.
Vasculitis International is pleased to extend its warmest congratulations to the Vasculitis Foundation (VF) on the occasion of its 40th anniversary. On behalf of the
Vasculitis International has published its position statement on the ongoing regulatory review of TAVNEOS® (avacopan) — and warns that data integrity and risk/benefit analysis are two very different issues and must not be treated as one, when taking action. Otherwise the patient pays for science failure.
The FDA has moved from a review to a formal proposal to withdraw approval of Tavneos in the United States.
This is a more serious step than a review, but it is still not a final decision.
In Europe, the EMA review is still ongoing. No conclusions have been reached yet, and Tavneos is still available.
